1) Motzer RJ, Hutson TE, Tomczak P, et al.: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356: 115-124, 2007
2) Motzer RJ, Hutson TE, Tomczak P, et al.: Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27 : 3584-3590, 2009
3) Naito S, Yamamoto N, Takayama T, et al.: Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era : a cooperative group report of 1,463 patients. Eur Urol 57 : 317-325, 2010
4) Shinohara N, Kumagai A, Kanagawa K, et al.: Multicenter phase II trial of combination therapy with meloxicam, a cox-2 inhibitor, and natural interferonalpha for metastatic renal cell carcinoma. Jpn J Clin Oncol 39 : 720-726, 2009
5) Ito N, Eto M, Nakamura E, et al.: STAT3 polymorphism predicts interferon-alfa response in patients with metastatic renal cell carcinoma. J Clin Oncol 25 : 2785-2791, 2007